JP Morgan Chase’s Xeris Biopharma Holdings XERS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$3.43M Sell
612,479
-282,580
-32% -$1.87M ﹤0.01% 3671
2025
Q4
$7.03M Sell
895,059
-10,017
-1% -$78.8K ﹤0.01% 3014
2025
Q3
$7.37M Sell
905,076
-127,186
-12% -$845K ﹤0.01% 3001
2025
Q2
$4.82M Sell
1,032,262
-1,082,447
-51% -$4.96M ﹤0.01% 3208
2025
Q1
$11.6M Buy
2,114,709
+1,071,268
+103% +$4.32M ﹤0.01% 2409
2024
Q4
$3.54M Buy
1,043,441
+651,481
+166% +$2.1M ﹤0.01% 3683
2024
Q3
$1.12M Buy
391,960
+67,557
+21% +$174K ﹤0.01% 4397
2024
Q2
$730K Sell
324,403
-49,952
-13% -$101K ﹤0.01% 4470
2024
Q1
$827K Buy
374,355
+51,919
+16% +$134K ﹤0.01% 4478
2023
Q4
$758K Buy
322,436
+205,480
+176% +$379K ﹤0.01% 4521
2023
Q3
$218K Sell
116,956
-185,400
-61% -$425K ﹤0.01% 5020
2023
Q2
$792K Sell
302,356
-463,935
-61% -$1.18M ﹤0.01% 4222
2023
Q1
$1.25M Buy
766,291
+671,873
+712% +$841K ﹤0.01% 3885
2022
Q4
$126K Buy
94,418
+10,096
+12% +$14.3K ﹤0.01% 5257
2022
Q3
$132K Buy
84,322
+4,712
+6% +$7.79K ﹤0.01% 5159
2022
Q2
$123K Buy
79,610
+60,955
+327% +$129K ﹤0.01% 5318
2022
Q1
$48K Buy
18,655
+5,398
+41% +$13.2K ﹤0.01% 5816
2021
Q4
$39K Buy
13,257
+8,629
+186% +$18.6K ﹤0.01% 6029
2021
Q3
$11K Buy
4,628
+1,509
+48% +$4.38K ﹤0.01% 6160
2021
Q2
$13K Sell
3,119
-14,115
-82% -$53.9K ﹤0.01% 6007
2021
Q1
$78K Sell
17,234
-3,115
-15% -$16.8K ﹤0.01% 5441
2020
Q4
$100K Buy
20,349
+3,215
+19% +$16.1K ﹤0.01% 4994
2020
Q3
$100K Sell
17,134
-2,639,449
-99% -$10.6M ﹤0.01% 4696
2020
Q2
$7.07M Buy
2,656,583
+2,648,064
+31,084% +$9.22M ﹤0.01% 2181
2020
Q1
$17K Sell
8,519
-222
-3% -$955 ﹤0.01% 4985
2019
Q4
$62K Hold
8,741
﹤0.01% 5055
2019
Q3
$86K Buy
8,741
+1,417
+19% +$15.9K ﹤0.01% 4960
2019
Q2
$79K Sell
7,324
-2,119
-22% -$22.2K ﹤0.01% 5011
2019
Q1
$95K Buy
9,443
+7,734
+453% +$99.1K ﹤0.01% 4903
2018
Q4
$29K Buy
1,709
+177
+12% +$3.55K ﹤0.01% 5243
2018
Q3
$27K Buy
+1,532
New +$33.3K ﹤0.01% 5364

Other funds holding XERS